These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 15731496)

  • 1. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.
    Falcone C; Emanuele E; D'Angelo A; Buzzi MP; Belvito C; Cuccia M; Geroldi D
    Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1032-7. PubMed ID: 15731496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.
    Chiang KH; Huang PH; Huang SS; Wu TC; Chen JW; Lin SJ
    Coron Artery Dis; 2009 Jun; 20(4):267-73. PubMed ID: 19440065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease.
    Catalano M; Cortelazzo A; Santi R; Contino L; Demicheli M; Yilmaz Y; Zorzetto M; Campo I; Lanati N; Emanuele E
    Clin Biochem; 2008 Aug; 41(12):981-5. PubMed ID: 18538667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
    Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
    Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans.
    Jang Y; Kim JY; Kang SM; Kim JS; Chae JS; Kim OY; Koh SJ; Lee HC; Ahn CW; Song YD; Lee JH
    Metabolism; 2007 Feb; 56(2):199-205. PubMed ID: 17224333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population.
    Norata GD; Garlaschelli K; Grigore L; Tibolla G; Raselli S; Redaelli L; Buccianti G; Catapano AL
    Nutr Metab Cardiovasc Dis; 2009 Feb; 19(2):129-34. PubMed ID: 18595673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients.
    Yokota C; Minematsu K; Tomii Y; Naganuma M; Ito A; Nagasawa H; Yamaguchi T
    J Neurol Sci; 2009 Dec; 287(1-2):41-4. PubMed ID: 19801152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.
    Kalousová M; Jáchymová M; Mestek O; Hodková M; Kazderová M; Tesar V; Zima T
    Nephrol Dial Transplant; 2007 Jul; 22(7):2020-6. PubMed ID: 17347281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis.
    Basta G; Castagnini M; Del Turco S; Epistolato MC; Righini P; Sangiorgi GM; De Caterina R; Tanganelli P
    Eur J Clin Invest; 2009 Dec; 39(12):1065-72. PubMed ID: 19811526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients.
    Hernanz A; De la Fuente M; Navarro M; Frank A
    Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.
    Emanuele E; D'Angelo A; Tomaino C; Binetti G; Ghidoni R; Politi P; Bernardi L; Maletta R; Bruni AC; Geroldi D
    Arch Neurol; 2005 Nov; 62(11):1734-6. PubMed ID: 16286548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble receptor for advanced glycation end products in patients with decreased renal function.
    Kalousová M; Hodková M; Kazderová M; Fialová J; Tesar V; Dusilová-Sulková S; Zima T
    Am J Kidney Dis; 2006 Mar; 47(3):406-11. PubMed ID: 16490618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control.
    Pullerits R; Bokarewa M; Dahlberg L; Tarkowski A
    Arthritis Res Ther; 2005; 7(4):R817-24. PubMed ID: 15987483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of feto-maternal infection/inflammation by the soluble receptor for advanced glycation end products (sRAGE): results of a pilot study.
    Hájek Z; Germanová A; Koucký M; Zima T; Kopecký P; Vítkova M; Parízek A; Kalousová M
    J Perinat Med; 2008; 36(5):399-404. PubMed ID: 18771410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity.
    Sternberg Z; Weinstock-Guttman B; Hojnacki D; Zamboni P; Zivadinov R; Chadha K; Lieberman A; Kazim L; Drake A; Rocco P; Grazioli E; Munschauer F
    Mult Scler; 2008 Jul; 14(6):759-63. PubMed ID: 18505774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Diabetes Metab Res Rev; 2008 Feb; 24(2):109-14. PubMed ID: 17694504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer.
    Tesarová P; Kalousová M; Jáchymová M; Mestek O; Petruzelka L; Zima T
    Cancer Invest; 2007 Dec; 25(8):720-5. PubMed ID: 18058469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy-associated plasma protein a and soluble receptor for advanced glycation end products after kidney transplantation.
    Kalousová M; Bartosová K; Zima T; Skibová J; Teplan V; Viklický O
    Kidney Blood Press Res; 2007; 30(1):31-7. PubMed ID: 17237617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD).
    Leonardis D; Basta G; Mallamaci F; Cutrupi S; Pizzini P; Tripepi R; Tripepi G; De Caterina R; Zoccali C
    Nutr Metab Cardiovasc Dis; 2012 Sep; 22(9):748-55. PubMed ID: 21470837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.